GeneThera to Attend Western Veterinary Conference in Las Vegas


WHEAT RIDGE, Colo. and NEWPORT BEACH, Calif., Feb. 13, 2009 (GLOBE NEWSWIRE) -- GeneThera, Inc. (Pink Sheets:GTHR), a leading international biotechnology company dedicated to improving food safety, will attend the Western Veterinary Conference February 15-19th in Las Vegas.

The Western Veterinary Conference is one of the largest single assemblies of veterinary practitioners in the world. The Conference provides comprehensive, current, and completely practical continuing education information for veterinary practitioners and veterinary paraprofessionals.

"GeneThera will be attending the conference to meet with distributors and customers. We have communicated with the major players and we are confident we will see a positive outcome," stated Dr. Tony Milici of GeneThera. "Our company has already been contacted by some of the larger cattle ranches in the United States, Canada, Mexico, and Brazil."

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

The GeneThera, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5876

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.



            

Contact Data